Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.

We assessed the safety, tolerability and preliminary efficacy of riociguat, a soluble guanylate cyclase stimulator, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In this open-label, uncontrolled pilot trial, patients received oral riociguat (1.0-2.

Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.

Objective: To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg.

Background: Poor response to sumatriptan therapy for acute migraine attacks has been documented in the literature, but few controlled trials have investigated the efficacy of an alternative triptan in this subgroup of patients.

Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.

Objective: To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg.

Background: Poor response to sumatriptan therapy for acute migraine attacks has been documented in the literature, but few controlled trials have investigated the efficacy of an alternative triptan in this subgroup of patients.

[New aspects in pain research at Bayer].

Considerable advances in the fields of molecular biology and pain research during the last decade has led to the identification of a wide range of pharmacological targets for new analgesics. Genes of interesting targets may be regulated either upwards or downwards under pathophysiological, i. e.